CHRS: Don’t Miss Coherus’ New Stock Offering Opportunity!

Overview – A Strategic Shift and Recent Offering

Coherus Oncology, Inc. (NASDAQ: CHRS) – formerly Coherus BioSciences – has undergone a major strategic transformation in the past two years. The company pivoted away from its biosimilar drug portfolio to focus exclusively on immuno-oncology. In 2024–2025 Coherus divested its last three biosimilar franchises (Lucentis biosimilar CIMERLI, Humira biosimilar YUSIMRY, and Neulasta biosimilar UDENYCA) for upfront proceeds totaling over $700 million (www.fiercepharma.com) (www.sec.gov). These sales left Coherus with a single commercial product – LOQTORZI (toripalimab-tpzi), a next-generation PD-1 inhibitor in-licensed from Junshi Biosciences – and a pipeline of novel cancer immunotherapies (www.fiercepharma.com) (www.fiercepharma.com). Management explicitly refocused on “innovative immuno-oncology programs” built around LOQTORZI in combination with its development candidates (an IL-27 antagonist and a CCR8 antibody) (www.biospace.com).

Most recently, Coherus seized a capital-raising opportunity via a new stock offering. On February 12, 2026, the company announced an underwritten public offering of 28.6 million new common shares at $1.75 per share (www.biospace.com). This pricing was at a significant discount (about 13% below the ~$2.01 market price prior to the announcement) (za.investing.com), reflecting investor caution. The gross proceeds are expected to be $50.1 million (or ~$57.7 million if underwriters exercise their option for an additional 4.29 million shares) (www.biospace.com) (za.investing.com). The offering is set to close by Feb. 17, 2026, and all shares are being sold by the company (i.e. new issuance) (www.biospace.com). Coherus plans to deploy the net proceeds to support LOQTORZI’s ongoing U.S. commercialization, advance clinical development of its pipeline candidates (CHS-114 and casdozokitug), and for general corporate purposes (www.biospace.com). In effect, this is a dilutive but necessary capital infusion to extend Coherus’ cash runway and bridge the funding gap until key drug trial readouts in 2026 (www.ainvest.com) (www.ainvest.com).

Shareholder Impact: This equity raise will dilute existing shareholders by roughly 25% (28.6 million new shares on a base of ~116 million outstanding as of Q3 2025 (www.sec.gov)). However, management acted proactively – raising cash before cash on hand runs low – to avoid a liquidity crunch ahead of pivotal clinical catalysts (www.ainvest.com) (www.ainvest.com). For investors, the move represents a classic trade-off: it strengthens the balance sheet (adding ~$50M cash) at the cost of immediate dilution and a lower share price. Institutional investors face a binary risk-reward calculus: the offering extends Coherus’ funding runway into 2027, hopefully long enough to see pipeline results, but if those results disappoint, the company might require further dilutive financing (www.ainvest.com) (www.ainvest.com).

Dividend Policy and Yield

Coherus does not pay any dividend on its common stock. In fact, the company has never declared or paid cash dividends historically and explicitly states it intends to retain all earnings to fund growth, with no plans to initiate dividends for the foreseeable future (www.sec.gov). As a clinical-stage oncology company incurring net losses, Coherus prioritizes reinvesting capital into R&D and commercialization rather than returning cash to shareholders. Consequently, the stock’s dividend yield is 0%. Metrics like FFO or AFFO (used in REIT valuation) are not applicable here, given Coherus’s biotech business model and negative operating cash flow. Any investor returns will derive solely from stock price appreciation, if the company’s strategy succeeds (www.sec.gov).

Financial Position – Leverage, Liquidity, and Coverage

Coherus has taken bold steps to de-lever its balance sheet using the windfall from asset sales. The December 2024 agreement to divest UDENYCA (pegfilgrastim biosimilar) to Intas Pharmaceuticals for $483.4 million upfront (plus $75 million in milestones) was transformative (www.biospace.com). Upon closing this deal in April 2025, Coherus used part of the proceeds to fully retire its $230 million convertible notes due 2026, and paid $49 million to buy out UDENYCA-related royalty obligations (www.biospace.com) (www.sec.gov). By Q3 2025, the convertible debt was essentially gone, with only ~$0.1M principal remaining outstanding (www.sec.gov).

Earlier in 2024, Coherus had also eliminated a large term loan. It sold its Lucentis biosimilar (CIMERLI) to Sandoz for $187.8 million (March 2024) and its YUSIMRY (adalimumab) franchise to a partner for $40 million (June 2024) (www.sec.gov). Proceeds were immediately applied to pay down a $250 million term loan that was originally due 2027 (www.sec.gov). In fact, by May 2024 the final $75 million of that loan was prepaid (www.globenewswire.com). Coherus financed this payoff through a combination of a new 2029 term loan (principal $38.7 million) and a revenue participation deal: on May 8, 2024, the company borrowed $38.7M (net $37.5M after discount) and sold the rights to a portion of future U.S. net sales of UDENYCA and LOQTORZI for another $37.5M (www.sec.gov). These funds together wiped out the 2027 loan entirely (www.sec.gov). After the UDENYCA sale in Q2 2025, Coherus even bought out the UDENYCA portion of that revenue-sharing agreement with a one-time $47.7M payment to the counterparty (www.sec.gov). This leaves only the LOQTORZI-linked revenue share in effect, essentially a small ongoing royalty obligation on U.S. LOQTORZI sales.

Current Leverage: As of late 2025, Coherus’s balance sheet carries minimal debt. The primary interest-bearing liability is the remaining $38.7M term loan due 2029, which is far smaller than the debt loads Coherus carried in prior years. Total liabilities dropped dramatically after the divestitures and note repayments (www.sec.gov) (www.sec.gov). The company’s interest expense has likewise fallen – interest from continuing operations was only $2.3M in Q3 2025, down from $2.8M a year prior (www.globenewswire.com). Interest coverage is not a concern now given Coherus’s large net cash position, though we note that earnings are still negative (so traditional EBITDA/interest ratios are not meaningful). With effectively no major debt maturities until 2029, Coherus has no near-term refinancing risk. The large convertible due 2026 was taken off the table well ahead of schedule (www.sec.gov).

Cash and Liquidity: Coherus’s cash reserves remain significant relative to its market size. Upon completing the UDENYCA sale in April 2025, the company had about $250 million in cash on its balance sheet (www.biospace.com). By the end of Q3 2025, Coherus still held $191.7 million in cash, equivalents and marketable securities (www.globenewswire.com), even after funding operations and pipeline development. This cash level was bolstered by the earlier asset sales and has given Coherus an extended operating runway. Management indicated that existing cash (plus any small at-the-market equity sales already made) would be sufficient to fund at least 12 months of expenses from the Q3 reporting date (www.sec.gov) – effectively through late 2026. The new $50M stock offering in Feb. 2026 will further augment the cash balance, offsetting ongoing burn and extending the runway roughly another 2–3 quarters.

Crucially, Coherus expects that its post-offering cash (~$240M) will fund the company past multiple key R&D milestones in 2026. Management previously projected that a ~$250M post-close cash balance (after the UDENYCA deal) would sustain operations “over two years into 2027” (www.biospace.com). The latest raise reinforces this buffer. In short, Coherus has transformed its capital structure: from a heavily leveraged biotech to a mostly debt-free company with a war chest of cash to invest in its oncology pipeline.

Coverage Ratios: Given negative earnings, Coherus has no positive EBITDA or FFO to calculate a coverage ratio in the traditional sense. However, the elimination of interest-bearing debt means interest payments are very low (only ~$6–8M per year in 2024–25) (www.globenewswire.com), easily covered by the company’s cash on hand. The more pertinent “coverage” question is whether Coherus’s cash + revenue can cover its R&D and operating expenses for the foreseeable future – effectively a measure of cash burn. At present, Coherus continues to run at a net loss (see below), so it is drawing down cash each quarter. Thus, the company’s cash runway – how many quarters of operating cash consumption can be covered by existing cash – is a key metric to watch. By management’s and our estimates, the runway now likely extends to mid or late 2027 barring unforeseen changes (www.biospace.com) (www.ainvest.com). This assumes no major revenue surprise or drastically higher spending. It’s worth noting Coherus also has an at-the-market (ATM) equity program in place (about $65M capacity remaining as of Q3 2025) that it could tap gradually for additional liquidity if needed (www.sec.gov) (www.sec.gov).

Valuation – Market Perception and Comparables

Coherus’s valuation has contracted significantly alongside its business overhaul. The stock now trades in the low-$2 range (recent offering priced at $1.75), down from the mid-$4s in early 2023 (www.biospace.com) and much higher levels in years prior. At ~$1.75/share, Coherus’s market capitalization is around $220–260 million (depending on full exercise of the new shares). Notably, this market cap is almost on par with Coherus’s cash balance post-offering – meaning the enterprise value (EV) implied by the market is very modest, essentially valuing the company’s drug portfolio and pipeline at only tens of millions of dollars. This cash-heavy valuation reflects skittish investor sentiment. In effect, Wall Street is assigning little credit to Coherus’s future prospects until more proof emerges. The stock’s current valuation “barely exceeds the company’s cash on hand”, signaling significant skepticism (www.ainvest.com).

Traditional valuation multiples are less useful for a company in Coherus’s situation (negative earnings and evolving revenue base). The price-to-earnings (P/E) ratio is not meaningful since Coherus remains in a net loss position. The price-to-sales (P/S) multiple is somewhat informative: Coherus reported $267.0 million in net revenue for full-year 2024 (www.nasdaq.com), so the stock currently trades at ~0.8× 2024 sales. However, that sales figure included the divested products; going forward, annual revenue will be much lower (coming mainly from LOQTORZI). For reference, 2023 total revenue was $257.2M (www.fiercepharma.com), of which ~half came from UDENYCA ($127.1M) and the rest from other biosimilars and initial LOQTORZI sales. In 2025, with only partial UDENYCA contribution (Q1) and growing LOQTORZI sales, revenues will dip substantially. Through Q3 2025, LOQTORZI had generated about $27 million (Q1–Q3 combined) (www.globenewswire.com), on pace for ~$40 million annualized. Thus, on a forward-looking basis, Coherus is trading at a very high P/S multiple relative to its near-term oncology-only revenue – indicating that investors are valuing the company mostly on pipeline potential rather than current sales.

Another lens is price-to-book (P/B). Coherus’s book value was boosted by the cash influx from asset sales; the Q3 2025 shareholder equity was substantial given the $191.7M cash and relatively low remaining liabilities (www.sec.gov) (www.sec.gov). The new $50M equity raise further increases book equity. We estimate P/B is modest (likely under 1.5×) after the offering, again highlighting that the market is not placing a large premium on Coherus’s intangible assets or pipeline. Essentially, Coherus is valued only slightly above a “liquidation value” (cash minus debt), implying the market has low expectations for its drug development efforts at this stage. This conservative valuation could present an opportunity for investors who have conviction in Coherus’s pipeline – any clinical or commercial success beyond the low expectations could lead to significant upside re-rating. Conversely, the thin EV means the downside may be somewhat buffered by cash (i.e. the stock already reflects a scenario close to net cash value).

Comparable Companies: Pure-play small-cap immuno-oncology companies often trade primarily on pipeline milestones, and Coherus is no exception. Many development-stage biotechs with one approved product and a pipeline trade at valuations driven by hope of future indications (often resulting in EV being a fraction of total invested capital). Coherus’s situation is somewhat unique in that it does have a commercial product (LOQTORZI) generating revenue, whereas many early-stage biotechs have none. Some comparables might include companies like Iovance Biotherapeutics (IOVA) or ARCUS Biosciences (RCUS) – each has a pipeline of immunotherapy candidates and minimal revenue. Those trade at market caps of a few hundred million to ~$1B, despite no profits, based on their lead assets. Coherus’s ~$250M valuation and one marketed drug places it at the lower end of the spectrum. It’s worth noting that Coherus’s valuation is a far cry from industry leaders: PD-1 inhibitor market giants like Merck (Keytruda) or Bristol Myers (Opdivo) are valued in the tens of billions, but of course those firms have massive diversified portfolios. Coherus is a micro-cap focused on a niche. The market will likely continue to value CHRS stock based on binary clinical outcomes and the trajectory of LOQTORZI’s sales rather than on traditional multiples. As one analysis put it, Coherus is currently “a pure-play on a handful of clinical catalysts, making it high-conviction, high-risk…and unsuitable for core holdings but potentially a tactical add for those seeking asymmetric upside” (www.ainvest.com). In summary, the upside in Coherus’s valuation lies in successful execution of its pipeline (which could dramatically alter the company’s earnings outlook), while the downside appears somewhat cushioned by its strong cash position.

Operational Performance and Coverage Metrics

Although Coherus’s corporate structure has been overhauled, the company is still working toward profitability. Earnings from continuing operations are negative, reflecting heavy R&D and SG&A expenditures to develop and market its oncology drugs. For Q3 2025, Coherus reported a net loss (continuing ops) of $44.5 million (–$0.38 per share), similar to the $47.6M loss in Q3 2024 (www.globenewswire.com). On a year-to-date basis, the net loss for the first 9 months of 2025 was $136.8M (improved from a $169.3M loss in the same period of 2024) (www.globenewswire.com). The narrowing losses reflect cost-cutting and the discontinuation of prior operations (biosimilar units), but Coherus is still far from breakeven. Operating cash flow is deeply negative, given these losses and the working capital needs to launch LOQTORZI. The company’s Adjusted EBITDA or FFO are not reported, but would also be negative once non-cash items are added back, because the core issue is that expenses significantly outweigh revenues right now.

However, Coherus’s cash burn rate has moderated somewhat post-divestitures. Research & development (R&D) expense was $77.9M for the first nine months of 2025, up slightly year-on-year as Coherus ramped investment in its IL-27 and CCR8 programs (www.globenewswire.com). Selling, general & administrative (SG&A) expense was $77.0M for the same 9-month period, down from $95.9M in 2024, thanks to headcount reductions and narrower focus (www.globenewswire.com). The company undertook a ~30% workforce reduction in 2024 to streamline for oncology (www.fiercepharma.com), contributing to lower overhead. These cost controls, plus the exit of the lower-margin biosimilar business, have improved Coherus’s cost structure.

Interest coverage (EBIT/interest) is negative since EBIT is negative. But as noted, interest expense has become a trivial portion of expenses – only $6.8M for first 9 months 2025 (www.globenewswire.com), versus ~$155M in operating expenses (R&D+SGA) over the same period. In effect, operating losses – not interest – are the main drag on financial performance. Coherus’s ability to cover its obligations relies on its cash reserves and any revenue from LOQTORZI rather than current profits. On that front, LOQTORZI sales are growing but still relatively small: net revenue was $11.2M in Q3 2025, up 12% from $10.0M in Q2 and +92% from $5.8M in Q3 2024 (www.globenewswire.com). This strong growth trajectory is encouraging, but even at ~$40–50M annualized, LOQTORZI’s revenue cannot yet cover Coherus’s ~$200M+ annual operating costs. Dividend coverage is not applicable since no dividends are paid.

Going forward, investors should watch a few coverage-related indicators closely:

- Cash Burn vs. Cash Reserves: At the current burn rate (~$40–50M net loss per quarter), Coherus’s ~$240M pro forma cash will last roughly 5–6 quarters. The company must either significantly ramp up revenues or reduce expenses (or both) to avoid needing additional funding after that. Management is using the offering proceeds to ensure they reach critical data readouts before cash runs low (www.ainvest.com) (www.ainvest.com).

- LOQTORZI Revenue Growth: This is the only meaningful internal cash generation for now. LOQTORZI’s sales trend (which was +12% sequentially in Q3 2025 (www.globenewswire.com)) needs to continue or accelerate. If quarterly LOQTORZI sales can climb into, say, the ~$20M+ range over the next year or two, it would help offset cash burn and demonstrate market traction. Coherus has noted that LOQTORZI is the only FDA-approved treatment for nasopharyngeal carcinoma (NPC) in the U.S., and uptake is growing especially as updated NCCN clinical guidelines have given it preferred status for NPC (www.globenewswire.com) (www.globenewswire.com). Still, NPC is a rare cancer, and about half of NPC patients are treated by community oncologists who may adopt new therapies slowly (www.globenewswire.com). So Coherus expects gradual, steady penetration in that niche. Broader label expansions (new cancer indications) would be needed to dramatically grow LOQTORZI’s addressable market.

- External Funding/Partnerships: Coherus’s strategy includes seeking “capital-efficient external partnerships for label expansions” of LOQTORZI (www.globenewswire.com). For example, it has partnered with a small biotech (ENB Therapeutics) to test LOQTORZI + ENB-003 in ovarian cancer (www.globenewswire.com). Any partnership deals that bring in external capital (upfront payments or cost-sharing) could improve Coherus’s funding position and reduce the need for future stock offerings. Conversely, failure to secure partnerships for expensive Phase 3 trials would mean Coherus might have to finance those on its own, possibly requiring more cash than currently planned.

- Milestone Payments: Coherus has potential incoming cash from the Intas deal milestones – two payments of $37.5M each if UDENYCA sales by Intas reach certain thresholds (www.sec.gov). These are essentially earn-outs from the biosimilar sale. It’s uncertain if/when they will be achieved (that depends on Intas’s commercial performance with UDENYCA post-acquisition). If they come through, that’s an extra $75M that could extend Coherus’s runway further without dilution. Investors should watch Intas’s updates or Coherus’s reports for any hint of those milestone triggers being met.

In summary, Coherus’s financial condition is a tale of two sides: balance sheet strength vs. income statement weakness. The company has fortified its balance sheet (ample cash, little debt) but continues to post sizable operating losses. The new equity raise shores up liquidity for the medium term, but improved coverage of costs will ultimately depend on increasing LOQTORZI revenue and/or pipeline success leading to partnerships or milestone payouts. Until then, the company will carefully manage its cash to cover the high R&D spend needed for its clinical trials.

Pipeline and Growth Outlook

Coherus’s investment thesis now hinges on the progress of its oncology pipeline and the expansion of LOQTORZI’s use beyond NPC. The company’s two key pipeline candidates – CHS-114 (a cytolytic anti-CCR8 Treg-depleting antibody) and casdozokitug (an IL-27 antagonist) – were acquired via Coherus’s September 2023 takeover of Surface Oncology (www.biospace.com) (www.biospace.com). Both are in Phase 1/2 development for various solid tumors, mostly in combination with LOQTORZI (the idea being to boost LOQTORZI’s efficacy by modulating the tumor microenvironment).

Upcoming Catalysts: Coherus has laid out an ambitious clinical roadmap for 2026. Multiple trial data readouts are expected in 2026 across different cancer settings (www.globenewswire.com) (www.ainvest.com), including: - CHS-114 (CCR8 antibody) – Initial efficacy data in head & neck squamous cell carcinoma (Phase 1b combo with toripalimab) anticipated in 1H 2026, and first look at CHS-114 + toripalimab in esophageal cancer around mid-2026 (www.globenewswire.com). A new cohort in colorectal cancer was also recently added, expanding CHS-114’s potential market (www.globenewswire.com) (www.ainvest.com). - Casdozokitug (IL-27 antagonist) – Early results from a Phase 2 trial in first-line hepatocellular carcinoma (casdozokitug + toripalimab + bevacizumab) expected by mid-2026 (www.globenewswire.com). This trial could prove whether IL-27 blockade adds benefit in liver cancer. - Additional studies (e.g. CHS-114 in 4L colorectal, combinations in NSCLC, etc.) with data likely later in 2026 (www.globenewswire.com).

These readouts are truly crucial catalysts. Positive clinical results could “de-risk the pipeline, validate the scientific approach, and dramatically alter valuation” (www.ainvest.com). Significant efficacy signals would not only boost investor confidence but could attract licensing or partnership interest from larger pharma companies. Conversely, disappointing data would raise questions about Coherus’s strategy and could leave the company with only the modest LOQTORZI revenue stream to fall back on. In essence, Coherus’s future value will be determined by whether one or more of these pipeline assets proves successful.

LOQTORZI Expansion: Aside from pipeline trials of new agents, Coherus is also working to broaden LOQTORZI’s own label. Currently approved only for nasopharyngeal carcinoma (a small indication), toripalimab has shown activity in other cancers (it’s approved in China for melanoma, for instance). Coherus’s approach is to combine LOQTORZI with other therapies to target new indications. For example: - In ovarian cancer, LOQTORZI is being tested in combination with a novel endothelin inhibitor (ENB-003) in a Phase 2 platform study (www.globenewswire.com). - In esophageal cancer, as noted, LOQTORZI + CHS-114 ± chemo is under study (www.globenewswire.com). - The company also mentions label-expanding partnerships: working with external organizations to pursue additional uses of LOQTORZI in a cost-effective way (www.globenewswire.com). One such partnership was a license of toripalimab’s Canadian rights to Apotex in mid-2024 for $6.3M (www.sec.gov), indicating Coherus is open to regional deals.

It’s important to recognize that Loqtorzi (toripalimab) faces competition as a PD-1 inhibitor. Globally, there are many PD-1/L1 antibodies (Merck’s Keytruda, BMS’s Opdivo, etc.), but most big players did not focus on nasopharyngeal carcinoma specifically. Toripalimab is first-to-market for NPC in the U.S., which gives it a unique niche. However, for larger cancer indications (lung cancer, melanoma, etc.), toripalimab would go up against entrenched giants with massive trial budgets and salesforces. Coherus likely cannot compete head-on in broad indications, so its strategy is to find niches or combinations where toripalimab can differentiate. The CCR8 and IL-27 combo approach is one such attempt – if successful, Coherus could carve out a role in treating tumors by removing immunosuppressive T-reg cells (CCR8+) or inhibitory cytokine signaling (IL-27) in concert with PD-1 blockade. This is a cutting-edge but high-risk approach; it’s scientifically intriguing (notably, the 2025 Nobel Prize in Medicine highlighted the importance of T-reg cells in cancer (www.globenewswire.com)), yet unproven in practice.

Management’s View: CEO Denny Lanfear has stated that Coherus is now “an innovative, revenue-generating oncology company with a strong balance sheet and a promising mid-stage pipeline” (www.biospace.com). The company believes it has sufficient capital to achieve “mid-term objectives” – specifically, maximizing LOQTORZI sales in NPC and advancing its pipeline to key data milestones in 2026 (www.biospace.com) (www.biospace.com). By late 2026, Coherus expects to have multiple data readouts that, if positive, could lead to pivotal trials or partnerships. Essentially, Coherus is in an execution phase: it must successfully enroll and complete ongoing studies, generate compelling clinical data, and continue to drive LOQTORZI adoption in its current market. Each quarter until then, investors will be evaluating two growth metrics: LOQTORZI sales trajectory and pipeline clinical progress.

Risks and Red Flags

Despite the opportunity presented by Coherus’s pipeline, investors should be mindful of several risk factors and red flags:

- Single-Product Reliance: After selling off its biosimilar drugs, Coherus now depends on one marketed product (LOQTORZI) for all revenue (www.fiercepharma.com). LOQTORZI’s current approved use (NPC) is an ultra-niche indication; U.S. NPC incidence is limited, which inherently caps near-term sales. While Coherus hopes to expand toripalimab’s indications, any setback with LOQTORZI (such as a new competing therapy for NPC, safety issues, or slower uptake) would severely impact the company’s only revenue stream. Essentially, Coherus has no diversification on the commercial side anymore – a classic high risk for a small biotech.

- Pipeline Execution Risk: Coherus’s valuation now hinges on its early- to mid-stage pipeline, which must clear significant clinical hurdles. Neither CHS-114 nor casdozokitug has proven efficacy in a pivotal trial yet. As with any biotech, there is a real possibility that some of these studies could fail to meet endpoints or show only modest benefits. The company’s entire thesis of combining toripalimab with novel immunotherapies is still unvalidated – it’s an experimental approach that could just as easily fail to improve outcomes. Negative or inconclusive trial results in 2026 would be devastating to the stock’s outlook. Investors should recognize this as a binary clinical risk, characteristic of biotech: success could multiply the stock value, but failure could erase a large portion of it.

- Cash Burn and Dilution: Though Coherus has bolstered its cash reserves, it continues to burn cash at a rate of ~$40+ million per quarter (www.globenewswire.com). If the pipeline development costs run higher than expected or trials face delays, Coherus might burn through its cash faster than anticipated. In such a scenario, the company could be forced into another capital raise before meaningful data arrives (www.ainvest.com). This overhang of potential future dilution is a constant concern. The recent offering itself, priced at a discount to market, immediately reduced existing shareholders’ value per share (za.investing.com) (www.ainvest.com). Any indication that Coherus’s cash runway is shortening (e.g. due to trial expansions or a commercial shortfall) could pressure the stock as investors pre-empt the next funding round. In short, financing risk remains – the current cash should last into 2027, but not indefinitely. Importantly, Coherus has no guarantee of receiving the $75M UDENYCA earn-outs; if those don’t materialize and if LOQTORZI sales don’t ramp up enough, additional funding needs in late 2027 or 2028 are possible.

- Competitive and Regulatory Risks: Coherus operates in a fiercely competitive field. PD-1/L1 inhibitors are a crowded class – while toripalimab carved out NPC, any attempts at broader use will encounter major competitors (Merck, BMS, etc.) who have far greater resources. Big Pharma could also develop their own CCR8 or IL-27 targeting drugs; Coherus’s head start via Surface’s assets is no guarantee of market success. Additionally, Coherus relies on partners for its drug supply and some trials (e.g. Junshi for toripalimab manufacturing). There are geopolitical risks too – toripalimab is originally developed in China; U.S.-China regulatory or trade issues could potentially impact supply or collaboration. On the regulatory front, Coherus must secure FDA approvals for any new indications or pipeline drugs. Given the novelty of its therapies, there may be higher regulatory scrutiny or requirement for extensive data. Any hiccup in approvals (e.g. CRLs, additional trials requested by FDA) would delay commercialization timelines.

- Integration and Focus Risk: Coherus rapidly restructured its business – selling three product lines and acquiring a new company (Surface) within about a year. Such rapid change can pose integration challenges. The Surface acquisition came with certain assets that Coherus already wrote off (e.g. GSK’s cancer program and NZV930 were discontinued, leading to impairment charges and CVR liabilities being written down) (www.globenewswire.com). While Coherus appears to have taken the best assets (CHS-114, IL-27) forward, it raises the question of how smoothly the R&D teams merged and whether any distractions or culture clashes exist after these changes. Moreover, Coherus’s leaner organization (post layoffs) must now handle both commercial activities (marketing LOQTORZI) and intense clinical development – a lot to juggle for a small company. Execution missteps (in trial management or marketing) are a risk given limited bandwidth.

- Stock Volatility and Ownership: The stock’s low absolute price and small market cap make it susceptible to volatility. It’s not unusual for biotech stocks like CHRS to swing wildly on news or sentiment. Furthermore, Coherus’s shareholder base is relatively concentrated (around 220 institutional holders, according to some analyses (www.ainvest.com)). If a few significant holders lose confidence (e.g. due to the dilutive offering or changed investment mandates), the stock could face selling pressure. On the flip side, if new institutions take positions, it could stabilize or lift the stock. This concentration means insider or institutional sentiment is crucial to watch – any big moves by top shareholders might signal shifting confidence.

- Open Regulatory/Partner Questions: Coherus’s long-term success will likely require partnering or co-development for large Phase 3 trials (especially if targeting big indications). It remains uncertain which external partners might come on board, or on what terms. If Coherus cannot strike advantageous partnerships, it may have to either fund huge trials alone (impractical given its size) or limit its ambitions to smaller indications. Additionally, Coherus’s ability to expand LOQTORZI’s label will depend on clinical outcomes – any need to run additional trials or if data are borderline, the timeline to new approvals could extend, delaying revenue growth.

Overall, Coherus presents a high-risk profile common to clinical-stage biotech companies. The near-term red flags are the ongoing cash burn and dilution, and the heavy reliance on unproven pipeline outcomes. The company’s strategic focus is bold and could yield significant rewards, but investors should calibrate their position size to account for the binary nature of the outcomes. As one commentary noted, Coherus stock carries a “risk premium…elevated until the binary data events in 2026 provide clarity” (www.ainvest.com). In other words, expect the stock to remain volatile and driven by news flow, with downside risk if execution falters.

Open Questions for Investors

As Coherus navigates the next 18–24 months, several open questions will determine the stock’s ultimate trajectory:

- Can LOQTORZI Achieve Commercial Traction (or Even Profitability)? – LOQTORZI’s launch in NPC has shown encouraging growth (+92% YoY revenue in Q3 2025) (www.globenewswire.com). But will this drug gain enough adoption to meaningfully offset Coherus’s expenses? With only a few hundred NPC patients treated per year in the U.S., LOQTORZI’s current market is limited. Will Coherus succeed in expanding LOQTORZI to new indications (through trials or partnerships) to broaden its revenue base? The company is actively educating oncologists and cites improved NCCN guideline positioning as a driver for uptake (www.globenewswire.com). However, it remains to be seen if that translates into sustained, exponential sales growth or just steady incremental gains. This question is critical because robust LOQTORZI revenues could reduce Coherus’s reliance on external financing. A related question is how margins and costs for LOQTORZI trend – Coherus likely pays a royalty to Junshi on sales, and it must manage marketing costs for a niche drug. The path to profitability would require not only sales growth but also careful cost management.

- Will 2026 Pipeline Readouts Validate Coherus’s Strategy? – By late 2026, Coherus is expected to deliver data from multiple trials of CHS-114 and casdozokitug (www.ainvest.com). This is the make-or-break moment for the pipeline. Positive results could “de-risk” these programs and dramatically boost Coherus’s value (and perhaps enable licensing deals or even make Coherus an acquisition target). Negative or inconclusive results would conversely raise doubts about the entire immunotherapy strategy and could leave Coherus with little to show after heavy R&D spending. Investors are essentially waiting on these binary outcomes. Key questions include: How strong will the efficacy signals be? Will the data be compelling enough to attract a partner or justify moving into Phase 3? Encouraging early data could allow Coherus to raise capital again at higher prices (or partner) from a position of strength – whereas weak data might leave it scrambling. Until these questions are answered, the stock will likely trade on anticipation (or anxiety) around these events.

- Is Further Dilution Inevitable, or Can Coherus Become Self-Sustaining? – Coherus has roughly two years of cash runway post-offering (www.biospace.com), giving it some breathing room. But if the pipeline requires larger Phase 3 trials or if revenues don’t ramp up, will the company need to raise more money in 2027 or beyond? This ties back to the outcomes of the above points. An open question is whether the current raise is the last one before Coherus reaches a self-funding stage. If LOQTORZI and pipeline progress exceed expectations, Coherus might not need another dilutive round – it could potentially fund late-stage trials via partnerships or with revenue contributions. However, if development timelines extend or costs increase, the specter of another capital raise (ATM usage or another public offering) will return. Investors should monitor Coherus’s quarterly cash burn closely relative to plans. As noted, the market already “prices in the probability of future raises” due to high R&D costs (www.ainvest.com) (www.ainvest.com). Clarity on this will come as we see clinical results and any business development deals.

- How Will Major Shareholders React Post-Offering? – Coherus’s investor base largely consists of institutional biotech funds. Now that the company has executed a dilutive offering at $1.75, an open question is: Will current large shareholders stay the course, or reduce exposure? The absence of a steep selloff after the announcement would indicate some confidence remaining. It will be insightful to watch any SEC filings (13-D/G or 13-F) or company commentary on ownership changes. If top holders add to positions at these depressed prices, it could signal conviction that the pipeline will pay off. Conversely, an “exodus” of key holders would be a red flag indicating loss of faith (www.ainvest.com). New investors taking stakes (perhaps specialized oncology investors or even a strategic investor) could also alter the sentiment around CHRS. Essentially, the vote of confidence (or lack thereof) from smart money in coming months is an open question.

- External Factors – Partnerships or M&A? – Given Coherus’s situation, one cannot ignore the possibility of corporate development events. Will Coherus strike a major partnership or be acquired? Larger pharma companies continuously scout for immuno-oncology assets. If Coherus’s CCR8 or IL-27 programs show promise, a collaboration deal (e.g. co-developing and co-marketing the drug, with Coherus receiving upfront cash) could be on the table. Such a deal could instantly answer funding concerns. Similarly, if toripalimab combinations look compelling, Coherus itself might become a takeover candidate for a company wanting a foothold in this niche. On the flip side, if no partner emerges even after good data, that would raise the question of whether Coherus can go it alone in Phase 3. No explicit offers are known at this time, so this remains speculative – but the strategic optionality is a real consideration for investors with a 1–2 year view.

In conclusion, Coherus Oncology (CHRS) presents a high-risk, potentially high-reward scenario centered on an emerging immuno-oncology story. The recent stock offering has fortified its finances (“extended the balance sheet runway” (www.ainvest.com)) and given investors a chance to buy in at levels near the company’s cash value. The bull case is that Coherus’s focused strategy – fueled by sufficient cash – will yield clinical breakthroughs in 2026, transforming the valuation and justifying today’s dilution. The bear case is that the pipeline might falter or require more time/money, in which case today’s shareholders could be diluted further or see value erode. With no dividend and ongoing losses, Coherus is not a traditional income investment but rather a speculative growth play. “Don’t miss Coherus’ new offering opportunity” is thus a double-edged sentiment – while the low valuation and strong cash position are attractive, only investors comfortable with significant clinical risk should dive in. This is a stock to watch closely over the next 18 months, as each trial result and revenue report will be critical in determining whether CHRS is a turnaround success or another biotech cautionary tale.